Biovian at BIO-Europe Spring March 9-11, 2015
Biovian's CEO, Dr. Knut Ringbom will be available for in-depth discussions with your delegates at the partnering offered at the conference.
Biovian's CEO, Dr. Knut Ringbom will be available for in-depth discussions with your delegates at the partnering offered at the conference.
Atlant Clinical is proud to announce its expansion to Western Europe by establishing its presence in Munich, Germany.
The ground-breaking sensitivity of Malvern Instruments’ new OMNISEC gel permeation chromatography/size exclusion chromatography system generated significant excitement from scientists meeting at the Seventh International Symposium on the Separation and Characterization of Natural and Synthetic Macromolecules (SCM-7), when the system made a well-received debut late in January.
Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has announced the launch of its Catalytic Reaction Guide (CRG) as a free mobile application.
The new Parsum IPP-80 probe from Malvern Instruments brings easy to integrate inline particle size measurement for efficient process monitoring and control. Suitable for powders, pellets and granules the new probe enables the real-time monitoring of agglomeration, coating and granulation processes.
Fef Chemicals A/S has confirmed that it will change its name to Novo Nordisk Pharmatech A/S as of September 1st 2015.
A new whitepaper from Malvern Instruments provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion. 'Analytical techniques with a place in the oral solid dosage formulation toolkit' reviews the regulatory and QbD framework associated with OSD formulation and demonstrates how Malvern systems can be used to generate the data required.
Suicide Risk Assessment System to Identify and Enable Treatment for At-Risk Students.
ECG Device Donations Enable Effective Cardiac Health Monitoring throughout Haiti.
Combined Offering Enables Real Time Decision Making in Global Clinical Trials.